OncoMed Pharma (OMED) Misses Q4 EPS by 23c

OncoMed Pharma (NASDAQ: OMED) reported Q4 EPS of ($0.50), $0.23 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $8.52 million versus the consensus estimate of $18.2 million.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79